$0.33
0.00 (-0.21%)
Open$0.34
Previous Close$0.33
Day High$0.34
Day Low$0.32
52W High$5.30
52W Low$0.31
Volume—
Avg Volume2.49M
Market Cap3.48M
P/E Ratio—
EPS$-5.33
SectorBiotechnology
Analyst Ratings
Strong Sell
7 analysts
Price Target
+8,644.7% upside
Current
$0.33
$0.33
Target
$28.63
$28.63
$25.08
$28.63 avg
$44.18
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 522.6K | 738.7K | 3.56M |
| Net Income | -55,234,051 | -70,272,329 | 452.9K |
| Profit Margin | -10,567.2% | -10,038.8% | 12.7% |
| EBITDA | -44,975,649 | -60,399,867 | 509.0K |
| Free Cash Flow | — | — | 445.4K |
| Rev Growth | -29.3% | -29.3% | +0.2% |
| Debt/Equity | — | — | 0.51 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $249.68 | -0.45% | 118.6 | 430.95B |
| AMGN | Amgen Inc | $412.84 | -1.20% | 25.1 | 219.39B |
| GILD | Gilead Sciences Inc | $138.12 | -0.01% | — | 165.85B |
| VRTX | Vertex Pharmaceuticals Inc | $508.33 | -1.57% | 28.3 | 124.51B |
| REGN | Regeneron Pharmaceuticals | $803.64 | -0.29% | 18.4 | 79.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $227.29 | +0.07% | 35.2 | 28.41B |